US2013116171A1PendingUtilityA1

Methods for treating metabolic disorders using fgf

52
Individually held — no corporate assignee on recordPriority: Apr 16, 2010Filed: Apr 18, 2011Published: May 9, 2013
Est. expiryApr 16, 2030(~3.7 yrs left)· nominal 20-yr term from priority
Inventors:Johan W. JonkerMichael DownesRonald M. EvansJaemyoung Suh
A61P 43/00A61P 3/10A61P 3/06A61P 3/00A61P 3/04A61P 1/16A61K 31/4439A61K 9/0019A61K 47/61A61K 45/06A61K 38/1825A61K 47/60
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition for treating a metabolic disorder in an individual comprising an FGF-1 compound. 
     
     
         2 . The composition of  claim 1 , wherein the FGF-1 compound is a functional fragment of FGF-1. 
     
     
         3 . The composition of  claim 1 , wherein the FGF-1 compound is a functional analog of FGF-1. 
     
     
         4 . The composition of  claim 1 , wherein the composition is formulated for intravenous administration. 
     
     
         5 . The composition of  claim 1 , wherein the composition is formulated for subcutaneous administration. 
     
     
         6 . The composition of  claim 1 , wherein the metabolic disorder is selected from elevated blood glucose, impaired glucose tolerance, insulin resistance, type II diabetes, obesity, elevated percent body fat, and fatty liver disease. 
     
     
         7 . The composition of  claim 1 , wherein the dose of the FGF-1 compound in the composition is equivalent to 0.01-1 mg FGF-1 per kg body weight. 
     
     
         8 . A method for treating a metabolic disorder in an individual, comprising administering an FGF-1 compound to the individual, thereby treating the metabolic disorder. 
     
     
         9 . The method of  claim 8 , wherein the metabolic disorder is selected from elevated blood glucose, impaired glucose tolerance, insulin resistance, type II diabetes, obesity, elevated percent body fat, and fatty liver disease. 
     
     
         10 . The method of  claim 8 , wherein the metabolic disorder is elevated percent body fat or obesity. 
     
     
         11 . The method of  claim 8 , wherein the metabolic disorder is selected from elevated blood glucose, impaired glucose tolerance, and insulin resistance. 
     
     
         12 . The method of  claim 8 , wherein the metabolic disorder is type II diabetes. 
     
     
         13 . The method of  claim 8 , wherein the metabolic disorder is fatty liver disease. 
     
     
         14 . The method of  claim 8 , wherein the FGF-1 compound is administered intravenously. 
     
     
         15 . The method of  claim 8 , wherein the FGF-1 compound is administered subcutaneously. 
     
     
         16 . The method of  claim 8 , wherein the FGF-1 compound is administered in combination with an additional therapeutic compound. 
     
     
         17 . The method of  claim 8 , wherein the FGF-1 compound is a functional fragment of FGF-1. 
     
     
         18 . The method of  claim 8 , wherein the FGF-1 compound is a functional analog of FGF-1. 
     
     
         19 . The method of  claim 8 , wherein the FGF-1 compound is administered at a dose equivalent to 0.01-1 mg FGF-1 per kg body weight. 
     
     
         20 . The method of  claim 8 , wherein the FGF-1 compound is administered once per day or less.

Join the waitlist — get patent alerts

Track US2013116171A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.